查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年囊肿纤维化市场预测：按药物类别、治疗方法、给药途径、配销通路和地区进行的全球分析
市场调查报告书
商品编码
1383350

2030 年囊肿纤维化市场预测：按药物类别、治疗方法、给药途径、配销通路和地区进行的全球分析

Cystic Fibrosis Market Forecasts to 2030 - Global Analysis By Drug Class, Treatment Method, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球囊肿纤维化市场规模为 114.9 亿美元，预计在预测期内复合年增长率为 22.4%，到 2030 年将达到 473 亿美元。

基因突变是导致囊肿纤维化(CF) 遗传疾病的原因。特定体液的蛋白质分泌受基因控制。这会影响身体的各个器官，并导致黏液和汗水变稠。此外，这种疾病会改变电解质输送系统，导致细胞吸收钠和水，进而导致负责分泌汗水和黏液的腺体出现问题。

根据囊肿纤维化患者登记处的数据，目前美国有超过 30,000 人患有这种疾病，估计全球约有 70,000 人患有这种疾病。

个人化医疗和基因检测

基因序列测定技术和基因检测的进步使得准确识别个别患者的 CFTR 基因突变成为可能。借助这种个体化方法，医疗专业人员可以根据每位患者的特定基因谱量身定制治疗计划并提供最合适的药物。此外，对个人化医疗的重视可以提高病患满意度和治疗效果，进一步激发市场活力。

昂贵的医疗费用

囊肿纤维化的治疗费用非常昂贵，尤其是 CFTR 调节剂，每年可达数十万美元。此类过度支出可能会让保险公司和卫生系统不堪重负，难以为所有患者提供服务。此外，对这些疗法的长期负担能力的担忧也可能是由成本驱动的，从而影响市场扩张。

改善药物传输系统

智慧型的进步正在改善治疗管理。然而，这些实用且高效的给药策略可确保患者获得治疗的全部益处，从而改善患者体验，促进医嘱遵从性，最终有助于扩大市场。

复杂的治疗计划

囊肿纤维化治疗计划通常涉及药物、治疗方法和生活方式改变之间的复杂相互作用。这种复杂性可能会让患者不知所措并降低治疗的医嘱遵从性。此外，违规可能会导致医疗费用增加和更频繁的病情恶化。

COVID-19 的影响：

COVID-19大流行也对患者治疗、临床试验和医疗保健系统造成重大干扰，影响了囊肿纤维化市场。这场大流行导致医疗资源紧张，减缓了新治疗方法的推出，并推迟了研究和开发。被诊断出患有囊肿纤维化的人被认为是高风险族群，经常面临更大的健康风险和获得必要医疗照护的机会有限。此外，大流行的经济影响增加了医疗保健系统和患者的经济负担，可能会影响囊肿纤维化治疗的成本和可用性。

囊肿纤维化跨膜传导调节剂调节剂部分预计在预测期内将是最大的

跨膜传导调节剂调节剂预计将为这种复杂且具有挑战性的遗传疾病的治疗带来范式转变，并且由于其变革性影响，预计将占据囊肿纤维化市场的最大份额。此外，跨膜传导调节剂（例如 Trikafta）已经改变了囊肿纤维化的治疗方法。这些药物透过解决导致囊肿纤维化的潜在遗传缺陷来改善黏液清除和氯离子转运。对于许多患有某些基因突变的患者来说，跨膜传导调节剂可显着改善肺功能，减少病情恶化，并改善生活品质。

预计吸入细分市场在预测期内复合年增长率最高

在囊肿纤维化市场中，吸入疗法领域的复合年增长率最高。近年来，吸入疗法变得越来越普及，因为它能够以有针对性且有效的方式将药物直接给药到肺部。吸入器通常用于囊性纤维化治疗，以输送药物来帮助控制囊肿纤维化的症状。此外，吸入剂领域的显着增长归因于多种因素，例如吸入技术的进步、对吸入疗法益处的认识不断提高以及专门用于吸入给药的新药物的开发。

比最大的地区

囊肿纤维化在北美拥有最大的市场占有率。这是由于支持该地区市场主导地位的几个因素。首先，在北美，无论是一般民众或医疗相关人员对囊肿纤维化的认知度都很高，医疗基础设施也很发达。这将有利于患者的早期诊断和治疗，扩大患者基础，并扩大囊肿纤维化治疗药物市场。此外，该地区拥有许多製药公司和研究机构，积极致力于开发尖端的囊肿纤维化治疗方法。最先进的医疗设备和优惠的医疗报销政策也推动了该地区的市场占有率。

复合年增长率最高的地区：

预计亚太地区囊肿纤维化市场的复合年增长率最高。该地区囊肿纤维化患者的数量不断增加，包括医疗保健在内的许多行业正在经历快速成长。该地区的快速增长归因于许多因素，包括公众对囊肿纤维化的认识不断提高、医疗基础设施的改善以及医疗费用的上升。此外，中国和印度等政府正在实施旨在使医疗保健更加负担得起和更容易获得的计划，提供更好的诊断和治疗选择，以帮助囊肿纤维化患者受益。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球囊肿纤维化市场：依药物类别

  • 介绍
  • 胰酵素补充剂
  • 黏液溶解剂
  • 支气管扩张剂
  • 抗生素
  • 囊肿纤维化跨膜传导调节剂
  • 其他药物类别

第6章全球囊肿纤维化市场：依治疗方法

  • 介绍
  • 药品
  • 装置

第7章全球囊肿纤维化市场：依给药途径

  • 介绍
  • 口服
  • 吸入

第8章全球囊肿纤维化市场：按配销通路

  • 介绍
  • 医院
  • 药局
  • 零售药房
  • 其他配销通路

第9章全球囊肿纤维化市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Pharmaxis Ltd
  • Gilead Sciences, Inc.
  • Teva Pharmaceuticals
  • Genentech Inc
  • AbbVie Inc.
  • Mylan NV
  • Viatris Inc.
  • Novartis AG
  • Allergan PLC
  • Pfizer Inc
  • Nestle Health Science
  • Hoffmann-La Roche AG
  • BayerAG
  • Vertex Pharmaceuticals Incorporated
  • AstraZeneca
  • Chiesi Farmaceutici SpA
  • Horizon Therapeutic Plc.
Product Code: SMRC24200

According to Stratistics MRC, the Global Cystic Fibrosis Market is accounted for $11.49 billion in 2023 and is expected to reach $47.30 billion by 2030 growing at a CAGR of 22.4% during the forecast period. A genetic mutation is the cause of the inherited disease known as cystic fibrosis (CF). Certain bodily liquids' protein secretion is regulated by genes. This affects different organs in the body, which tends to thicken mucus and sweat. Moreover, this illness modifies the electrolyte transport system, which results in the absorption of sodium and water by cells and causes issues with the glands responsible for producing sweat and mucus.

According to the Cystic Fibrosis Patient Registry, it is estimated that more than 30,000 people are currently suffering from this condition in the U.S. and it is estimated that about 70,000 people are suffering from it across the globe.

Market Dynamics:

Driver:

Personalized medicine and genetic testing

The ability to precisely identify CFTR gene mutations in individual patients has been made possible by advances in genetic sequencing technologies and genetic testing. With the help of this individualized approach, medical professionals can customize treatment plans and offer the best medications depending on each patient's particular genetic profile. Additionally, the market is further propelled by the emphasis on personalized medicine, which raises patient satisfaction and treatment effectiveness.

Restraint:

Expensive medical care

The cost of treating cystic fibrosis can be extremely high, sometimes amounting to hundreds of thousands of dollars per year, particularly for CFTR modulators. These excessive expenses may put pressure on insurers and healthcare systems, making it more difficult to provide access to all patients. Furthermore, concerns about these treatments' long-term affordability are also brought up by cost, which could have an impact on market expansion.

Opportunity:

Improvements in medication delivery systems

Treatment administration has been enhanced by advances in drug delivery, such as intelligent inhalers and effective nebulizers. However, since they guarantee that patients get the full benefit of their treatments, these practical and efficient drug delivery strategies improve patient experience, promote adherence, and subsequently aid in market expansion.

Threat:

Complex therapy plans

Treatment plans for cystic fibrosis frequently entail a complicated mix of drugs, therapies, and lifestyle modifications. This complexity has the potential to overwhelm patients and result in poor adherence to treatment, which will ultimately compromise the efficacy of therapies and patient outcomes. Moreover, healthcare expenses may rise, and exacerbations may occur more frequently as a result of noncompliance.

COVID-19 Impact:

The COVID-19 pandemic caused major disruptions in patient care, clinical trials, and healthcare systems, which in turn affected the cystic fibrosis market. The pandemic put a strain on healthcare resources, delayed the introduction of new treatments, and postponed research and development. Individuals diagnosed with cystic fibrosis, who were regarded as a high-risk population, experienced increased health risks and frequently had limited access to necessary medical care. Furthermore, the pandemic's economic effects put more strain on healthcare systems and patients' finances, which might have an impact on the cost and accessibility of cystic fibrosis treatments.

The Cystic Fibrosis Transmembrane Conductance Regulator Modulators segment is expected to be the largest during the forecast period

CFTR modulators are expected to hold the largest share in the cystic fibrosis market due to their transformative impact, which is expected to represent a paradigm shift in the treatment of this complex and challenging genetic disease. Moreover, treatment for cystic fibrosis has been transformed by CFTR modulators such as Trikafta. These medications improve mucus clearance and chloride transport by addressing the underlying genetic defect that causes cystic fibrosis. For many patients with particular genetic mutations, CFTR modulators greatly improve lung function, lower exacerbations, and improve quality of life.

The Inhaled segment is expected to have the highest CAGR during the forecast period

The inhaled segment of the cystic fibrosis market has the highest CAGR. Because inhaled therapies deliver medication directly to the lungs in a targeted and effective manner, they have become increasingly popular in recent years. Inhalers are commonly used in these therapies to deliver medications that assist in controlling the symptoms of cystic fibrosis. Additionally, the significant growth of the inhaled segment can be attributed to various factors, such as the progression of inhalation technology, heightened consciousness regarding the advantages of inhalation treatments, and the creation of novel medications especially intended for inhalation administration.

Region with largest share:

North America holds the largest market share for cystic fibrosis. This is explained by a number of factors that support the region's market dominance. First off, both the general public and medical professionals in North America are highly aware of cystic fibrosis, and the continent has a well-established healthcare infrastructure. This makes it easier to diagnose and treat patients early, which expands the patient pool and raises the market for cystic fibrosis treatments. Furthermore, there are many pharmaceutical companies and research facilities in the area that are actively working to develop cutting-edge cystic fibrosis treatments. The availability of cutting-edge medical equipment and advantageous reimbursement practices also boost the market share of the area.

Region with highest CAGR:

The Asia-Pacific region is anticipated to have the highest CAGR in the cystic fibrosis market. This region is seeing a rise in the number of cases of cystic fibrosis and is seeing rapid growth in a number of industries, including healthcare. The region's rapid growth is attributed to a number of factors, including expanding public awareness of cystic fibrosis, enhancing healthcare infrastructure, and rising healthcare costs. Moreover, governments in nations such as China and India are implementing programs aimed at improving healthcare affordability and accessibility, which will benefit patients with cystic fibrosis by providing better options for diagnosis and treatment.

Key players in the market

Some of the key players in Cystic Fibrosis market include: Pharmaxis Ltd , Gilead Sciences, Inc., Teva Pharmaceuticals, Genentech Inc , AbbVie Inc., Mylan N.V, Viatris Inc., Novartis AG, Allergan PLC, Pfizer Inc, Nestle Health Science, Hoffmann-La Roche AG , BayerAG, Vertex Pharmaceuticals Incorporated, AstraZeneca , Chiesi Farmaceutici SpA and Horizon Therapeutic Plc.

Key Developments:

In October 2023, Teva Pharmaceuticals and Sanofi have announced an agreement to jointly develop and commercialise a treatment for inflammatory bowel disease, with the deal potentially worth up to $1.5bn.The candidate, Teva's TEV'574, is an anti-TL1A therapy currently being evaluated in phase 2b clinical trials as a treatment for ulcerative colitis and Crohn's disease, the two main types of inflammatory bowel disease.

In October 2023, Viatris Inc., a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.

In September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical today announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope ("peptide-RI") drug conjugates.

Drug Classes Covered:

  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • Antibiotics
  • Cystic Fibrosis Transmembrane Conductance Regulator Modulators
  • Other Drug Classes

Treatment Methods Covered:

  • Medication
  • Devices

Route of Administrations Covered:

  • Oral
  • Inhaled

Distribution Channels Covered:

  • Hospital
  • Drug Stores
  • Retail Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cystic Fibrosis Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Pancreatic Enzyme Supplements
  • 5.3 Mucolytic
  • 5.4 Bronchodilators
  • 5.5 Antibiotics
  • 5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
  • 5.7 Other Drug Classes

6 Global Cystic Fibrosis Market, By Treatment Method

  • 6.1 Introduction
  • 6.2 Medication
  • 6.3 Devices

7 Global Cystic Fibrosis Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Inhaled

8 Global Cystic Fibrosis Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital
  • 8.3 Drug Stores
  • 8.4 Retail Pharmacies
  • 8.5 Other Distribution Channels

9 Global Cystic Fibrosis Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Pharmaxis Ltd
  • 11.2 Gilead Sciences, Inc.
  • 11.3 Teva Pharmaceuticals
  • 11.4 Genentech Inc
  • 11.5 AbbVie Inc.
  • 11.6 Mylan N.V
  • 11.7 Viatris Inc.
  • 11.8 Novartis AG
  • 11.9 Allergan PLC
  • 11.10 Pfizer Inc
  • 11.11 Nestle Health Science
  • 11.12 Hoffmann-La Roche AG
  • 11.13 BayerAG
  • 11.14 Vertex Pharmaceuticals Incorporated
  • 11.15 AstraZeneca
  • 11.16 Chiesi Farmaceutici SpA
  • 11.17 Horizon Therapeutic Plc.

List of Tables

  • Table 1 Global Cystic Fibrosis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 4 Global Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 5 Global Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 6 Global Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 7 Global Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 8 Global Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 9 Global Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 10 Global Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 11 Global Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 12 Global Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 14 Global Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 15 Global Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 16 Global Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 17 Global Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 18 Global Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 19 Global Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 20 North America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 22 North America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 23 North America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 24 North America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 25 North America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 26 North America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 27 North America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 28 North America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 29 North America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 30 North America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 31 North America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 32 North America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 33 North America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 34 North America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 35 North America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 36 North America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 37 North America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 38 North America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 39 Europe Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 41 Europe Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 42 Europe Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 43 Europe Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 44 Europe Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 45 Europe Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 46 Europe Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 47 Europe Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 48 Europe Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 49 Europe Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 50 Europe Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 51 Europe Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 52 Europe Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 53 Europe Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 54 Europe Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 55 Europe Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 56 Europe Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 58 Asia Pacific Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 60 Asia Pacific Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 61 Asia Pacific Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 62 Asia Pacific Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 63 Asia Pacific Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 64 Asia Pacific Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 65 Asia Pacific Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 66 Asia Pacific Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 67 Asia Pacific Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 68 Asia Pacific Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 69 Asia Pacific Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 70 Asia Pacific Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 71 Asia Pacific Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 72 Asia Pacific Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 73 Asia Pacific Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 74 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 75 Asia Pacific Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 77 South America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 79 South America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 80 South America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 81 South America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 82 South America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 83 South America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 84 South America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 85 South America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 86 South America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 87 South America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 88 South America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 South America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 90 South America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 91 South America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 92 South America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 93 South America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 94 South America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 95 South America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 96 Middle East & Africa Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 98 Middle East & Africa Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
  • Table 99 Middle East & Africa Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
  • Table 100 Middle East & Africa Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
  • Table 101 Middle East & Africa Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 102 Middle East & Africa Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
  • Table 103 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 104 Middle East & Africa Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
  • Table 105 Middle East & Africa Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 106 Middle East & Africa Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
  • Table 107 Middle East & Africa Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 108 Middle East & Africa Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 109 Middle East & Africa Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
  • Table 110 Middle East & Africa Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 111 Middle East & Africa Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 112 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 113 Middle East & Africa Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)